Amplia Therapeutics, ANZGOG Finalize Protocol for Phase Two Ovarian Cancer Trial; Shares Up 4%

MT Newswires Live

Yesterday

Amplia Therapeutics (ASX:ATX) and the Australia New Zealand Gynaecological Oncology Group (ANZGOG) have finalized the clinical trial protocol for the PRROSE phase two study, clearing a key milestone ahead of the trial's planned commencement, according to a Tuesday filing with the Australian bourse.

The trial will evaluate the company's focal adhesion kinase inhibitor narmafotinib in combination with standard chemotherapy in women with high-grade serous ovarian cancer whose tumors show a poor response to chemotherapy before interval debulking surgery, per the filing.

The study is expected to enroll around 26 patients at selected sites across Australia and New Zealand, with ethics and site approvals to be secured before patient recruitment begins by the end of the year, the filing added.

The company's shares rose 4% in recent Tuesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2667697967"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667697967\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667697967?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 09:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667697967","market":"fut","top_or_hot":-1,"title":"Amplia Therapeutics, ANZGOG Finalize Protocol for Phase Two Ovarian Cancer Trial; Shares Up 4%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) and the <a href=\"https://laohu8.com/S/ANZPH.AU\">Australia New Zealand</a> Gynaecological Oncology Group (ANZGOG) have finalized the clinical trial protocol for the PRROSE phase two study, clearing a key milestone ahead of the trial's planned commencement, according to a Tuesday filing with the Australian bourse.</p><p>The trial will evaluate the company's focal adhesion kinase inhibitor narmafotinib in combination with standard chemotherapy in women with high-grade serous ovarian cancer whose tumors show a poor response to chemotherapy before interval debulking surgery, per the filing.</p><p>The study is expected to enroll around 26 patients at selected sites across <a href=\"https://laohu8.com/S/AN3PF.AU\">Australia and New Zealand</a>, with ethics and site approvals to be secured before patient recruitment begins by the end of the year, the filing added.</p><p>The company's shares rose 4% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amplia Therapeutics, ANZGOG Finalize Protocol for Phase Two Ovarian Cancer Trial; Shares Up 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmplia Therapeutics, ANZGOG Finalize Protocol for Phase Two Ovarian Cancer Trial; Shares Up 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-15 09:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) and the <a href=\"https://laohu8.com/S/ANZPH.AU\">Australia New Zealand</a> Gynaecological Oncology Group (ANZGOG) have finalized the clinical trial protocol for the PRROSE phase two study, clearing a key milestone ahead of the trial's planned commencement, according to a Tuesday filing with the Australian bourse.</p><p>The trial will evaluate the company's focal adhesion kinase inhibitor narmafotinib in combination with standard chemotherapy in women with high-grade serous ovarian cancer whose tumors show a poor response to chemotherapy before interval debulking surgery, per the filing.</p><p>The study is expected to enroll around 26 patients at selected sites across <a href=\"https://laohu8.com/S/AN3PF.AU\">Australia and New Zealand</a>, with ethics and site approvals to be secured before patient recruitment begins by the end of the year, the filing added.</p><p>The company's shares rose 4% in recent Tuesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2667697967","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667697967","pubTimestamp":1789435858,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amplia Therapeutics  and the Australia New Zealand Gynaecological Oncology Group  have finalized the clinical trial protocol for the PRROSE phase two study, clearing a key milestone ahead of the trial's planned commencement, according to a Tuesday filing with the Australian bourse.The trial will evaluate the company's focal adhesion kinase inhibitor narmafotinib in combination with standard chemotherapy in women with high-grade serous ovarian cancer whose tumors show a poor response to chemotherapy before interval debulking surgery, per the filing.The study is expected to enroll around 26 patients at selected sites across Australia and New Zealand, with ethics and site approvals to be secured before patient recruitment begins by the end of the year, the filing added.The company's shares rose 4% in recent Tuesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK4139":"生物科技","LENZ":"Therapeutics","BK4539":"次新股","BK4007":"制药","ATX.AU":"AMPLIA THERAPEUTICS LTD"},"translate_title":"Amplia Therapeutics 和 ANZGOG 最终确定卵巢癌二期试验方案；股价上涨 4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"ATX.AU":1},"content_text":"Amplia Therapeutics (ASX:ATX) and the Australia New Zealand Gynaecological Oncology Group (ANZGOG) have finalized the clinical trial protocol for the PRROSE phase two study, clearing a key milestone ahead of the trial's planned commencement, according to a Tuesday filing with the Australian bourse.The trial will evaluate the company's focal adhesion kinase inhibitor narmafotinib in combination with standard chemotherapy in women with high-grade serous ovarian cancer whose tumors show a poor response to chemotherapy before interval debulking surgery, per the filing.The study is expected to enroll around 26 patients at selected sites across Australia and New Zealand, with ethics and site approvals to be secured before patient recruitment begins by the end of the year, the filing added.The company's shares rose 4% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}